Risk of ADRs from RCTs and prospective cohort studies
| ADRs | No. of events | Pooled incidence of ADRs per 100 patients* |
| Gastrointestinal disorders | ||
| Diarrhoea | 150 | 3.0 |
| Nausea and vomiting | 84 | 1.7 |
| Abdominal pain | 42 | 0.8 |
| Stomachache | 16 | 0.3 |
| Subtotal | 292 | |
| General disorders and administration site conditions | ||
| Fever | 85 | 1.7 |
| Pain in injection site | 74 | 1.5 |
| Localised pain | 4 | 0.1 |
| Thrombophelibitis | 10 | 0.2 |
| Arthralgia | 1 | <0.1 |
| Subtotal | 174 | |
| Skin and subcutaneous tissue disorders | ||
| Rash | 57 | 1.2 |
| Itching | 4 | 0.1 |
| Infusion site erythema | 2 | <0.1 |
| Subtotal | 63 | |
| Others | ||
| Stomatitis | 7 | 0.1 |
| Anorexia | 6 | 0.1 |
| Persistent hearing deficiencies | 2 | <0.1 |
| Otitis media | 1 | <0.1 |
| Subtotal | 16 | |
| Total | 545 | |
*The total number of patients is 4928.
ADRs, adverse drug reactions; RCTs, randomised controlled trials.